Carey Ng Biography and Net Worth

Director of Immix Biopharma

Dr. Ng is a Managing Director of Mesa Verde Venture Partners and Member of the Investment Committee. Dr. Ng has over fifteen years investment and operating experience in the biomedical industry, ranging from biotech startups to large biopharmaceutical companies.

Dr. Ng serves on the board of a number of Mesa Verde portfolio companies including Immix Biopharma, Elysium Therapeutics, Satiogen Pharmaceuticals (spinout acquired by Shire), Biscayne Neurotherapeutics (acquired by Supernus), and Paradigm (acquired by Exact Sciences). His board observer roles include Matrisys Bioscience, Immusoft, Alastin Skincare, Retrosense Therapeutics (acquired by Allergan), and Oncternal Therapeutics (ONCT). Prior to Mesa Verde, he worked with a number of biomedical startups and was also in business development at Abbott. Dr. Ng has a Ph.D. from UCLA and a MBA from UC San Diego.

What is Carey Ng's net worth?: The estimated net worth of Carey Ng is at least $163 thousand as of August 16th, 2024. Ng owns 20,000 shares of Immix Biopharma stock worth more than $163,000 as of March 27th. This net worth estimate does not reflect any other assets that Ng may own. Learn More about Carey Ng's net worth.
How do I contact Carey Ng?: The corporate mailing address for Ng and other Immix Biopharma executives is , , . Immix Biopharma can also be reached via phone at 310-651-8041. Learn More on Carey Ng's contact information.
Has Carey Ng been buying or selling shares of Immix Biopharma?: Carey Ng has not been actively trading shares of Immix Biopharma during the last ninety days. Most recently, on Friday, August 16th, Carey Ng bought 10,000 shares of Immix Biopharma stock. The stock was acquired at an average cost of $1.86 per share, with a total value of $18,600.00. Following the completion of the transaction, the director now directly owns 20,000 shares of the company's stock, valued at $37,200. Learn More on Carey Ng's trading history.
Who are Immix Biopharma's active insiders?: Immix Biopharma's insider roster includes Jason Hsu (Director), Gabriel Morris (CFO), Carey Ng (Director), and Ilya Rachman (CEO). Learn More on Immix Biopharma's active insiders.
Are insiders buying or selling shares of Immix Biopharma?: In the last twelve months, Immix Biopharma insiders bought shares 6 times. They purchased a total of 11,019 shares worth more than $30,275.04. The most recent insider tranaction occured on December, 10th when CEO Ilya M Rachman bought 746 shares worth more than $4,975.82. Insiders at Immix Biopharma own 55.4% of the company. Learn More about insider trades at Immix Biopharma.
Information on this page was last updated on 12/10/2025.

Carey Ng Insider Trading History at Immix Biopharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/16/2024	Buy	10,000	$1.86	$18,600.00	20,000
9/14/2023	Buy	10,000	$2.58	$25,800.00	10,000

Carey Ng Buying and Selling Activity at Immix Biopharma

Immix Biopharma Company Overview

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.

Today's Range

Now: $8.15

$8.00

$9.19

50 Day Range

MA: $7.70

$4.60

$11.12

2 Week Range

Now: $8.15

$1.34

$11.61

Volume

750,582 shs

Average Volume

889,096 shs

Market Capitalization

$431.62 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.25